drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A trispecific T-cell engager (multispecific antibody biologic) that binds CD3 on T cells and CD19/CD20 on B cells to redirect T-cell cytotoxicity against malignant B cells in relapsed/refractory B-cell non-Hodgkin lymphoma; administered with step-up then maintenance IV or SC dosing on 21-day cycles.
nci_thesaurus_concept_id
C188959
nci_thesaurus_preferred_term
Anti-CD3/CD19/CD20 Trispecific Antibody 1A46
nci_thesaurus_definition
A trispecific immunoglobulin G (IgG)-like T-cell engaging antibody targeting the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, and the T-cell surface antigen CD3, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD3/CD19/CD20 trispecific antibody 1A46 binds to CD19- and/or CD20-expressing tumor B-cell and CD3 antigen on cytotoxic T-lymphocytes (CTLs). This activates and redirects CTLs to CD19- and/or CD20-expressing tumor cells, resulting in CTL-mediated killing of tumor cells. Both CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies. Targeting both CD19 and CD20 may prevent tumor cell antigen escape and relapse.
drug_mesh_term
Antibodies, Bispecific
drug_category
TRISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous, Subcutaneous
drug_mechanism_of_action
IgG-like trispecific T-cell engager that simultaneously binds CD3 on T cells and CD19/CD20 on B cells, redirecting and activating cytotoxic T cells to kill CD19/CD20-expressing malignant B cells and reducing antigen-escape by dual B-cell targeting.
drug_name
1A46
nct_id_drug_ref
NCT05987605